Semaglutide, the blockbuster drug behind the global obesity-treatment revolution, has received one of its most careful scientific audits yet. A new systematic review published in BMC Endocrine Disorders has pulled together fifteen studies spanning randomized controlled trials, off-treatment extensions, and a propensity-matched observational cohort to answer a deceptively simple question: how well does the drug actually work for weight loss in adults with overweight or obesity, and at what cost to tolerability? The answer, according to researchers at King Khalid University in Saudi Arabia, is both encouraging and sobering, and it arrives at a moment when demand for GLP-1 receptor agonists has never been higher.
The review, conducted in accordance with the PRISMA 2020 reporting guidelines, searched PubMed, Web of Science, Cochrane CENTRAL, and Google Scholar for peer-reviewed studies published between 2015 and 2025. The team led by Razan Suliman Alhumayed included randomized trials and observational studies reporting weight-related outcomes with either oral or subcutaneous semaglutide. Because the included studies differed substantially in population, formulation, dose, indication, comparator, design, and follow-up duration, the authors chose a narrative synthesis rather than quantitative pooling, a decision that shapes how their conclusions should be read.
The headline finding concerns the obesity-focused trials that excluded diabetes. In these studies, once-weekly subcutaneous semaglutide at the 2.4-milligram dose, the regimen approved specifically for chronic weight management, generally produced mean weight reductions of approximately 14 to 17 percent over 68 weeks. For a patient weighing 100 kilograms, that translates to a loss of roughly 14 to 17 kilograms, a magnitude that rivals some bariatric surgical outcomes and far exceeds what lifestyle intervention alone typically achieves. A trial testing a higher 7.2-milligram regimen produced even greater weight loss, hinting at a dose-response relationship that could define the next generation of obesity pharmacotherapy.
The biology behind these numbers is central to understanding why semaglutide behaves the way it does. As a long-acting glucagon-like peptide-1 receptor agonist, the drug reduces appetite and energy intake through both central and gastrointestinal mechanisms, mimicking a gut hormone that signals satiety to the brain and slows gastric emptying. Available in subcutaneous and oral formulations, semaglutide is used across two major indications, obesity and type 2 diabetes mellitus, with dosing that differs by formulation and indication. That dual identity is precisely why the review’s authors insist the evidence must be interpreted in a population-specific way.
In studies of people with type 2 diabetes, the weight-loss picture changes noticeably. Reductions in body weight were smaller in the diabetes trials than in the obesity-focused studies, but they were accompanied by clinically important improvements in HbA1c, the standard measure of long-term blood glucose control. This distinction matters enormously for clinical practice. A patient with diabetes starting semaglutide should expect meaningful metabolic benefits alongside more modest weight changes, while a patient without diabetes on the higher obesity dose can anticipate the larger reductions. The review also separated out the oral formulation studies, which primarily enrolled participants with type 2 diabetes, and interpreted them distinctly from the obesity-dose subcutaneous trials rather than blending the evidence together.
Safety findings form the other half of the story, and they are unlikely to surprise clinicians who have watched GLP-1 prescriptions soar. Gastrointestinal adverse events, including nausea, vomiting, and diarrhea, were the most frequent tolerability issue across the included studies, and their frequency tended to increase during dose escalation and with higher cumulative exposure. This pattern reinforces the importance of gradual titration schedules, which are designed to let the body adapt before patients reach the maintenance dose. For most patients these effects are manageable, but they remain the leading reason people struggle with the treatment in its early months.
Beyond the digestive system, the review flagged several less common but clinically significant signals. Gallbladder events, treatment discontinuation, and a diabetic retinopathy signal observed in the SUSTAIN-6 cardiovascular outcomes trial all warrant careful, population-specific interpretation. The retinopathy finding, in particular, has implications for patients with diabetes and pre-existing eye disease, suggesting that clinicians should monitor vision in vulnerable groups when initiating therapy. None of these signals outweighs the drug’s demonstrated benefits, but they complicate the simple narrative of a miracle weight-loss injection that has dominated social media and popular coverage.
Perhaps the most sobering finding for the millions of people now taking or considering the drug concerns what happens when treatment stops. Weight regain after discontinuation was substantial in the withdrawal and extension studies included in the review. This observation underscores a biological reality that obesity specialists have long emphasized: obesity is a chronic disease, and pharmacotherapy that suppresses appetite works only while the drug is on board. Once treatment ends, the physiological drivers of weight regain reassert themselves, often erasing hard-won losses. The finding has significant implications for health systems and insurers weighing the cost of lifelong therapy against the consequences of relapse.
The review’s authors are careful about the limits of their own work. Because no quantitative pooling was performed, their conclusions are descriptive and should be interpreted cautiously. The strongest weight-loss evidence derives from obesity-focused subcutaneous trials, while findings from diabetes studies, cardiovascular outcome trials, oral formulation studies, and observational cohorts provide complementary but not directly interchangeable evidence. In an era when headlines often flatten these distinctions, the review serves as a reminder that the answer to how much weight a patient might lose depends heavily on who the patient is, which formulation they take, and at what dose.
What emerges from this comprehensive synthesis is a portrait of a genuinely transformative but imperfect therapy. Semaglutide is associated with clinically meaningful weight reduction, and for adults with obesity the 14 to 17 percent average losses achieved with the 2.4-milligram weekly injection represent a genuine turning point in obesity medicine. Yet the magnitude of benefit and the safety profile vary by population, formulation, dose, indication, and study design, and the substantial weight regain after discontinuation tempers any expectation of a permanent pharmacological fix. As prescriptions continue to climb worldwide, this review offers clinicians and patients alike a rigorously assembled evidence base for setting realistic expectations, managing side effects proactively, and planning for the long-term realities of chronic weight management.
Subject of Research: Efficacy and safety of semaglutide for weight loss in adults with overweight or obesity
Article Title: Efficacy and safety of semaglutide for weight loss among adults with overweight or obesity: a systematic review and narrative synthesis
Article References: Efficacy and safety of semaglutide for weight loss among adults with overweight or obesity: a systematic review and narrative synthesis. (n.d.). https://doi.org/10.1186/s12902-026-02641-z
Image Credits: AI Generated
DOI: 10.1186/s12902-026-02641-z
Keywords: semaglutide, obesity, weight loss, GLP-1 receptor agonists, systematic review, type 2 diabetes, gastrointestinal side effects, weight regain, subcutaneous injection, oral semaglutide, HbA1c, drug safety
News Source: Ophelia Keating. (October 13, 2026). Semaglutide Delivers 14–17% Weight Loss in Landmark Review, but Gains Fade After Stopping. Scienmag.
